Drug profile

The FDA adverse-event record for Propylene Glycol + Salicylic Acid

30 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Propylene Glycol + Salicylic Acid. Species, reactions, and outcomes follow.

#1456 of 2,679
by report volume (all drugs)
30
adverse-event reports
0.0%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Propylene Glycol + Salicylic Acid ranks #1440 of 2679 by total reports (30). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1440
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Propylene Glycol + Salicylic Acid has 30 reports now versus 28 in that prior snapshot: 2 more (7.1%).

Report change
+2
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Propylene Glycol + Salicylic Acid changes

Signature read: Propylene Glycol + Salicylic Acid's 0.0% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
30
Total Reports
0
Deaths Reported
0.0%
Death-coded share of reports

Active Ingredients

Propylene GlycolPropylene Glycol + Salicylic AcidSalicylic Acid

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 30

Most Affected Breeds

Retriever - Labrador 6
Terrier - Yorkshire 3
Pointer (unspecified) 2
Pointing Dog - Hungarian Short-haired (Vizsla) 2
Bulldog 2
Shepherd Dog - German 2
Boxer (German Boxer) 1
Terrier - West Highland White 1
Terrier - Rat 1
Bloodhound 1

Most Reported Reactions

Lack of efficacy - NOS 13
Loss of hearing 5
Vomiting 3
Abnormal cytology 3
Other abnormal test result NOS 2
Ear pain 2
Impaired hearing 2
Deafness 2
Sleepiness - systemic disorder 2
Ear discharge 2
Behavioural disorder NOS 2
Other ear disorder NOS 2

Outcome Breakdown

Outcome Unknown
18 (60.0%)
Ongoing
10 (33.3%)
Recovered/Normal
2 (6.7%)

Propylene Glycol + Salicylic Acid: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Propylene Glycol + Salicylic Acid (#1456 of 2,679 by report volume); death-coded 0.0%. PlainBreed drug row · death-coded share stamp 0.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →